GeneTether Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GTTX.CN research report →
Companygenetether.com
GeneTether Therapeutics Inc. , a genetic medicines company, focuses on developing gene editing therapies to enhance the efficiency of genome editing technologies. It is developing gene therapies for the treatment of patients with rare and monogenic kidney and skin diseases.
- CEO
- Roland Boivin
- IPO
- 2022
- HQ
- Kelowna, BC, CA
Price Chart
Valuation
- Market Cap
- $4.65M
- P/E
- -5.88
- P/S
- 0.00
- P/B
- 2.95
- EV/EBITDA
- 0.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -42.64%
- ROIC
- -54.46%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-688,359 · 59.82%
- EPS
- $-0.01 · 58.19%
- Op Income
- $-747,277
- FCF YoY
- 60.53%
Performance & Tape
- 52W High
- $0.12
- 52W Low
- $0.12
- 50D MA
- $0.07
- 200D MA
- $0.05
- Beta
- -1.56
- Avg Volume
- 2.95K
Get TickerSpark's AI analysis on GTTX.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our GTTX.CN Coverage
We haven't published any research on GTTX.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GTTX.CN Report →